BioHarvest Sciences (BHST) Expected to Announce Quarterly Earnings on Monday

Key Points

• BioHarvest Sciences (NASDAQ:BHST) is set to announce its Q2 2025 earnings on August 11, with analysts predicting a loss of ($0.11) per share and revenue of $8.53 million.
• In its previous earnings report on May 15, the company reported ($0.13) EPS which exceeded expectations, but revenue fell short at $7.64 million.
• Despite past performance, analysts maintain a positive outlook with a "buy" rating and price targets of $14.00 and $15.00 from HC Wainwright and Craig Hallum respectively.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect BioHarvest Sciences to post earnings of ($0.11) per share and revenue of $8.53 million for the quarter.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02. BioHarvest Sciences had a negative net margin of 31.30% and a negative return on equity of 307.04%. The company had revenue of $7.64 million for the quarter, compared to analysts' expectations of $8.93 million. On average, analysts expect BioHarvest Sciences to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioHarvest Sciences Trading Up 8.1%

BHST traded up $0.66 during trading hours on Friday, hitting $8.76. The company's stock had a trading volume of 68,578 shares, compared to its average volume of 8,541. The business's 50-day moving average price is $7.17 and its 200-day moving average price is $6.33. BioHarvest Sciences has a 12 month low of $4.66 and a 12 month high of $9.50. The stock has a market cap of $143.84 million, a price-to-earnings ratio of -17.52 and a beta of 0.68.

Analyst Ratings Changes

Separately, Craig Hallum assumed coverage on shares of BioHarvest Sciences in a research report on Monday, May 5th. They issued a "buy" rating and a $15.00 price target on the stock.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.